GenVec Inc. publicly shared its data concerning immune responses to its latest vaccine, GV2311 at a symposium Thursday in South Africa.
The vaccine implements GenVec’s proprietary gorilla adenovector platform intended to heighten the efficiency of gene-based vaccines like GV2311. Such heightened efficiency requires inducing high levels of response from both antibodies and T cells. These responses will boost immune responses for each administration of the vaccine.
The study candidates were mice immunized with Respiratory Syncytial Virus (RSV) and GV2311. Researchers took note of the T cells induced with the vaccine before and after the immunization.
Mice immunized with RSV showed no signs of a viral infection. Evidence revealed that GV2311 vaccination prevented the virus from entering the lungs and partially prevented the infection from settling in noses.
The tests’ evidence show GV2311 to be effective in provoking an antibody response against RSV. However, researchers do not underestimate the contribution of T cells to the immune system.
"We are excited about the potential of our vaccine to address this widespread disease that remains a significant health concern to very young children, the elderly, and immunocompromised individuals," GenVec's Chief Scientific Officer Dr. Douglas E. Brough said. "This novel vaccine construct has shown very promising preclinical results, and has the potential to provide protection without triggering vaccine-enhanced disease or being neutralized by maternal antibodies in infants."
Dr. Teresa R. Johnson, who chairs the microbiology and immunology department of Edward College of Osteopathic Medicine in Virginia, made the presentation at the ninth International Respiratory Syncytial Virus Symposium in South Africa.